Syndromic Testing Markets
Description
Syndromic Testing Markets
Saving sample volume, cutting down provider time, reducing costs, improving outcomes, these are goals of the healthcare system, and they are well suited to a test that can identify more than a single pathogen. It has been thought that numerous pathogens tested directly from clinical specimens could change up diagnostics, and many vendors have responded by producing syndromic multiplex panels with considerable capabilities. These single tests, designed to detect a number of organisms that might have caused a particular syndrome, are aimed at positively influencing decisions regarding patient management, infection control, and antimicrobial prescription decisions. On a more fundamental level- they can produce better test results, as they tend to find infections at a greater rate.
This Kalorama Information report includes the following important business data:
As of 2019, over 40 companies are active in the global market for liquid biopsy diagnostics and monitoring tests. The market for liquid biopsy testing, still in its infancy, is rapidly evolving as vendors develop and commercialize innovative new technologies to meet the needs of the clinical diagnostic market.
Geographically, the majority of participants in the liquid biopsy market are based in the United States, and to a lesser extent, Europe. A few companies are based in Asia. The competitive landscape is quite varied, with participants ranging from some of the world’s largest and most well-established diagnostics companies to small start-ups; Kalorama’s report provides extensive landscaping.
With the growing number of market entrants and available tests, competition is increasing. In the past two years, several new competitors entered the market, while several others have exited. However, with the rapidly growing market the heterogeneity of cancer as an umbrella term for many diseases, there are ample opportunities in the market to meet the needs of clinicians and patients. Kalorama’s report tracks these trends, identifies segment markets and separates research markets from those involving the detection and monitoring of disease.
Saving sample volume, cutting down provider time, reducing costs, improving outcomes, these are goals of the healthcare system, and they are well suited to a test that can identify more than a single pathogen. It has been thought that numerous pathogens tested directly from clinical specimens could change up diagnostics, and many vendors have responded by producing syndromic multiplex panels with considerable capabilities. These single tests, designed to detect a number of organisms that might have caused a particular syndrome, are aimed at positively influencing decisions regarding patient management, infection control, and antimicrobial prescription decisions. On a more fundamental level- they can produce better test results, as they tend to find infections at a greater rate.
This Kalorama Information report includes the following important business data:
- Selected Syndromic Test Panels
- Market for GI Syndromic Tests
- Market for Respiratory Syndromic Tests
- Market for HAI Syndromic Test Panels
- Market for Other Syndromic Testing
- Forecasts to 2023
- Company Profiles
As of 2019, over 40 companies are active in the global market for liquid biopsy diagnostics and monitoring tests. The market for liquid biopsy testing, still in its infancy, is rapidly evolving as vendors develop and commercialize innovative new technologies to meet the needs of the clinical diagnostic market.
Geographically, the majority of participants in the liquid biopsy market are based in the United States, and to a lesser extent, Europe. A few companies are based in Asia. The competitive landscape is quite varied, with participants ranging from some of the world’s largest and most well-established diagnostics companies to small start-ups; Kalorama’s report provides extensive landscaping.
With the growing number of market entrants and available tests, competition is increasing. In the past two years, several new competitors entered the market, while several others have exited. However, with the rapidly growing market the heterogeneity of cancer as an umbrella term for many diseases, there are ample opportunities in the market to meet the needs of clinicians and patients. Kalorama’s report tracks these trends, identifies segment markets and separates research markets from those involving the detection and monitoring of disease.
Table of Contents
37 Pages
- Syndromic Testing
- Advantages of Syndromic Testing
- Challenges of Syndromic Test Approaches
- Scope and Methodology
- Size and Growth in the Market
- Vendor Activity
- Recent Developments in Syndromic Testing
- Size of the Market by Indication
- Syndromic Testing Post-Palmetto Decision
- Abbott Laboratories
- Akonni Biosystems
- Becton, Dickinson and Company (BD)
- Biocartis NV
- bioMérieux Inc.
- Meridian Bioscience, Inc.
- Qiagen N.V.
- Siemens Healthineers
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.